Frequency of treatment-emergent aGVHD by site of disease after anti–PD-1 administration
| . | aGVHD stage . | |||
|---|---|---|---|---|
| Stage 1 (n = 4) . | Stage 2 (n = 1) . | Stage 3 (n = 8) . | Stage 4 (n = 6) . | |
| Skin | 1 | 1 | 5 | 1 |
| GI | 0 | 0 | 1 | 1 |
| Liver | 3 | 0 | 2 | 4 |
| . | aGVHD stage . | |||
|---|---|---|---|---|
| Stage 1 (n = 4) . | Stage 2 (n = 1) . | Stage 3 (n = 8) . | Stage 4 (n = 6) . | |
| Skin | 1 | 1 | 5 | 1 |
| GI | 0 | 0 | 1 | 1 |
| Liver | 3 | 0 | 2 | 4 |
aGVHD stage/grade and responses were scored according to Consensus criteria. Each episode of GVHD was recorded as either acute or chronic, although some patients experienced aGVHD and cGVHD, which were counted as mutually exclusive events.
GI, gastrointestinal.